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STATE OF THE ART: CONCISE REVIEW
Radiochemotherapy of Esophageal Cancer
Zhongxing Liao, MD, James D. Cox, MD, and Ritsuko Komaki, MD
Abstract: Cancer of the esophagus continues to be a threat to public
health. The common practice is esophagectomy for surgically re-
sectable tumors and radiochemotherapy for locally advanced, unre-
sectable tumors. However, local regional tumor control and overall
survival of esophageal cancer patients after the standard therapies
remain poor, approximately 30% of patients treated with surgery
only will develop local recurrence, and 50% to 60% patients treated
with radiochemotherapy only fail local regionally due to persistent
disease or local recurrence. Esophagectomy after radiochemo-
therapy or preoperative radiochemotherapy has increased the com-
plete surgical resection rate and local regional control without a
significant survival benefit. Induction chemotherapy followed by
preoperative radiochemotherapy has produced encouraging results.
In addition to patient-, tumor-, and treatment-related factors, in-
volvement of celiac axis nodes, number of positive lymph nodes
after preoperative radiochemotherapy, incomplete pathologic re-
sponse, high metabolic activity on positron emission tomography
scan after radiochemotherapy, and incomplete surgical resection are
factors associated with a poor outcome. Radiochemotherapy fol-
lowed by surgery is associated with significant adverse effects,
including treatment-related pneumonitis, postoperative pulmonary
complications, esophagitis and pericarditis. The incidence and se-
verity of the adverse effects are associated with chemotherapy and
radiotherapy dosimetric factors. Innovative treatment strategies in-
cluding physically and biologically molecular targeted therapy is
needed to improve the treatment outcome of patients with esopha-
geal cancer.
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Esophageal cancer has commanded increased attention inthe past three decades because of changing epidemiologic
patterns and expanded treatment options.1–4 Worldwide,
esophageal cancer is the sixth leading cause of cancer death,
and its 5-year survival rate in the United States is 14.9%.3,5 It
is the seventh most deadly cancer among men in the United
States, being responsible for 4% of all cancer deaths annually.3
In men, the incidence is highest in China (21.6/100,000),
some African nations (12.5–19.2/100,000), and Kazakhstan
(19.1/100,000). In the United States, the incidence is 2.1 per
100,000 in men and 1.2 per 100,000 in women and is
increasing, and in 2006, 14,550 new cases are anticipated
along with 13,770 deaths.2,3,6
The causes of esophageal cancer remain mostly elusive.
There has been a 350% increase in the incidence of adeno-
carcinoma of the lower esophagus and gastroesophageal junc-
tion.7 Adenocarcinoma has been associated with obesity,
gastroesophageal reflux disease, and Barrett’s esophagus.8 It
is believed that the widespread use of a proton pump inhibitor
for gastroesophageal reflux disease, which induces a long-
term achlohydria state, might be one of the potential mech-
anisms in the carcinogenesis of adenocarcinoma.9 Risk fac-
tors for squamous cell carcinoma include achalasia, tobacco
or alcohol use, caustic injury, a history of cancer, and cancer
treatment.1
Over the past two decades, advances in imaging tech-
nology have allowed more accurate staging of patients with
esophageal cancer and have led to better selection of patients
for different treatment modalities. Also, advances in radio-
therapy technique in particular, the development of three-
dimensional conformal radiotherapy, which allows better
strategic targeting of tumor volume and improved sparing of
normal tissue, have significantly improved patient outcomes.
This review discusses prognostic factors, definitive radioche-
motherapy, and preoperative radiochemotherapy in patients
with esophageal cancer and the rationale for these ap-
proaches, the evidence supporting their use, and side effects
of such treatment.
PROGNOSTIC FACTORS
An extensive systematic review of the staging investi-
gation, management, and prognostic factors for esophageal
cancer has been reposted by Wong and Malthaner.10 In brief,
staging of the esophageal cancer starts with a thorough
medical history and physical examination, although most of
the findings are nonspecific. The most common symptom
related to the primary tumor is dysphagia, an indication of
tumor invasion to the musculature and locally advanced
disease. The routine and most accurate diagnostic modality
for staging is a combination of esophagoduodegastroscopy
and biopsy, endoscopic ultrasonography (EUS), computed
tomography (CT), and positron emission tomography
(PET).11 EUS is generally considered the most accurate
method for T stage with accuracy of 60% to 95%. For nodal
stage, the accuracy of EUS is 65% to 90%, with an average
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sensitivity of 75% (range, 50%–88%) and specificity of 70%
(range, 33%–88%).10 PET has a sensitivity of 95% for
detecting the primary tumor; sensitivity ranges from 40% to
90%, specificity is greater than 70%, and accuracy ranges
from 48% to 86% for regional nodal disease. Sensitivity
ranges from 46% to 71%, specificity is 73% to 100%, and
accuracy ranges from 63% to 94% for distant metastases.10,12
Additionally, the significance of PET in target delineation for
esophageal cancer treatment planning as a functional image
modality is under extensive investigation.
For patients treated with surgery alone, the current
TNM staging system used to classify cancer of the esophagus
is a good reflection of significant prognostic factors, which
include depth of invasion (T), regional lymph node involve-
ment (N), and presence of distant metastasis (M).11 Depth of
invasion and the presence and number of the involved re-
gional lymph nodes are significant prognostic factors for
locally advanced esophageal cancer. Although there is a
difference in the risk factors and biological behavior between
adenocarcinoma and squamous cell carcinoma of the esoph-
agus, inconsistency exists in the reports on using histological
type and location of the primary as prognostic factors.13,14
Molecular target and tumor markers as prognostic factors and
in therapeutic approach are currently under intensive inves-
tigation. The current American Joint Committee on Cancer
staging system has been challenged by a number of investi-
gators,15,16 and a systematic review of this subject was per-
formed by Wong and Malthaner.10 The prognostic factors for
patients treated with preoperative radiochemotherapy and
surgery are not well defined, and the most common prognos-
tic factors for patients treated with neoadjuvant therapy and
surgery are listed in Table 1.17–22
Celiac Axis Nodes
Involvement of celiac adenopathy is a poor prognostic
factor, especially when patients are treated with surgery alone
or with preoperative radiochemotherapy.17,23,24 The involve-
ment of celiac axis usually indicates systemic spreading of
the disease and a poor prognosis. The 2002 American Joint
Committee on Cancer11 classifies celiac axis involvement as
a metastatic subset, M1a, rather than a N1 designation be-
cause of the high likelihood of relapse when surgery alone is
used. A recent study17 reviewed a single institutional experi-
ence with preoperative chemoradiotherapy in 186 patients
with adenocarcinoma of the distal esophagus and celiac
adenopathy identified with pretreatment EUS. All patients
were treated with preoperative concurrent radiochemotherapy
and esophagectomy or induction chemotherapy followed by
preoperative concurrent radiochemotherapy and esophagec-
tomy. The pretreatment EUS-identified celiac adenopathy
was a significant predictor of decreased long-term survival
(p  0.03). Median and 3-year survivals were 49 months and
54% in the EUS-identified cN0 M0 group (n  65), 45
months and 56% in the EUS-identified cN1 M0 group (n 
96), and 19 months and 12% in the EUS-identified celiac
adenopathy (cM1a) group (n  18; p  0.03). Increased
systemic relapse was noted in the EUS-identified cM1a group
(44% versus 22%, p  0.07). The only factor associated with
increased survival in the EUS-identified cM1a group (27
versus 15 months, p  0.02) was the addition of induction
chemotherapy before concurrent chemoradiotherapy and sur-
gical intervention. There seemed to be a tendency toward a
higher proportion of patients who had systemic as opposed to
locoregional relapse. The systemic relapse rate for patients with
celiac lymph node disease was 44% compared with 18% for
patients with no lymph node involvement and 26% for those
with periesophageal node involvement (p  0.07) (Figure 1).17
The fact that locoregional relapse was similar between the
groups and that induction chemotherapy before radiochemo-
therapy was associated with long-term survival suggests that
additional improvements in survival for patients with celiac
lymph node disease may need to focus on better systemic
control.17 Therefore, it is important to identify this high-risk
group before treatment and to evaluate the benefit of induc-
tion chemotherapy before concurrent radiochemotherapy in
an attempt to improve overall survival for this high-risk group
of patients.17 Catalano et al.25 found that preoperative detec-
tion of celiac lymph nodes by EUS with characterization by
size, shape, echogenicity, and borders had a sensitivity and
specificity of 83% and 98% for involvement. False positives
occurred in only two of 145 patients. Another study showed
that the mere detection of celiac axis lymph nodes was highly
predictive of malignant involvement, and celiac lymph nodes
greater than 10 mm have been shown in some studies to be
histologically involved 100% of the time.24
Response to Induction Therapy
In locally advanced squamous cell carcinoma, clinical
response to induction chemotherapy was the only indepen-
dent prognostic factor of local tumor control and long-term
survival in a phase II trial, where patients were treated with
induction chemotherapy followed by concurrent radiochemo-
TABLE 1. Prognostic Factors for Overall Survival in
Esophageal Cancer
Prognostic Factor 3-yr OS p
Pretreatment celiac node
positive17
54%–56% if celiac
node negative, 12%
if celiac node
positive
0.03
No. of positive node post-
radiochemotherapy18
0–1 positive node,
5-yr OS  34%–
38%; 2 positive
nodes, 5-yr OS 
6%
0.02
Post-radiochemotherapy
FDG-PET SUV19
SUV 4, 18-mo
survival  77%,
SUV 4, 18-mo
survival  34%,
0.01
R0 resection20 R0, 59%; R1, 37%;
R2, 4%
0.001
Complete pathologic
response21
pCR  74%; 1%–50%
residual  54%;
50% residual 
24%
0.001
Clinical tumor response to
induction chemotherapy22
50% vs. 17.9% 0.0001
OS, overall survival; SUV, standard unit value; pCR, percentage of complete
pathologic response.
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therapy and surgery.26 This finding was later confirmed by a
phase III randomized trial.22 Nonresponders to chemotherapy
who underwent surgery had a 79% probability of undergoing
complete tumor resection after radiochemotherapy, and al-
most all these patients had viable tumor within the resected
specimen.
Complete eradication of cancer cells in the surgical
specimen has consistently been recognized as a favorable
prognostic factor for locoregional control and overall survival
for esophageal cancer.27,28 Pathologic complete response was
reported in 2.5% to 5% of patients who received induction
chemotherapy alone before surgery,29,30 in 11% to 41% of
patients who received preoperative radiochemotherapy with
5-fluorouracil (5-FU) and cisplatin, in 17.7% to 46% of
patients who received preoperative paclitaxel-based concur-
rent radiochemotherapy, and in as many as 71% of patients
who received induction chemotherapy before preoperative
concurrent radiochemotherapy.31–35 Marked survival and lo-
cal control advantages have been noted for the patients who
achieved pathologic complete response in trials investigating
preoperative radiochemotherapy.36–39 In a study of 235 con-
secutive patients with pretherapy clinical stage II, III, or IVA
carcinoma of the esophagus or the esophagogastric junction
who were treated with radiochemotherapy followed by
esophagectomy, Chirieac et al.40 assessed the predictive value
of survival by posttherapy pathologic stage. Posttherapy can-
cer status was classified using pathologic stage and semiquan-
titative assessment of residual carcinoma. Clinicopathologic
features, residual carcinoma status, and pre- and posttherapy
stage were compared with disease-free and overall survival.
The results showed that cancer downstaging occurred in 56%
of patients on radiochemotherapy therapy before surgery.
Most interestingly, posttherapy pathologic stage was the
strongest predictor and an independent predictor of disease-
free and overall survival (both with p  0.02). Extent of
residual carcinoma was also a significant predictor of overall
survival (p  0.04). Based on this analysis, Swisher et al.21
have proposed revision of the esophageal cancer staging
system to accommodate pathologic response after preopera-
tive radiochemotherapy (Figure 2). These findings support
the concept of downstaging by preoperative therapy and
confirm the findings of others41–43 that preoperative radioche-
motherapy in locoregionally advanced esophageal cancer can
produce a complete or nearly complete response, as indicated
by pathologic findings, in a subset of patients.
Functional Imaging as a Prognostic Factor for
Radiochemotherapy
Currently, standard PET with the glucose analogue
fluorodeoxyglucose (FDG-PET) is widely employed for an-
atomic imaging and staging of esophageal cancer.44,45 Al-
though tumors use glucose to provide energy for growth, they
also use glucose to provide energy for other processes,
including cellular maintenance, cellular repair, and even ap-
optosis, programmed cell death.
FIGURE 2. Overall survival of patients with resected esoph-
ageal cancer treated with preoperative radiochemotherapy
and surgery according to pathologic response at primary
tumor (pP) (3 years: P0  0% residual  74%; P1  1%–
50% residual  54%; P2  50% residual  24%, p 
0.001). From Swisher SG, Hofstetter W, Wu TT, Correa AM,
Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A,
Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revi-
sion of the esophageal cancer staging system to accommo-
date pathologic response (pP) following preoperative
chemoradiation (CRT). Ann Surg 2005;241:810–7; discussion
817–20. Reprinted with permission from Lippincott Williams
& Wilkins.
FIGURE 1. Overall survival of patients with adenocarci-
noma of the distal esophagus according to pretreatment,
endoscopic ultrasonography–identified node status (cM1A
versus cN0M0, cN1M0; p  0.03). From Malaisrie SC, Hof-
stetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A,
Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier
R, Roth JA, Swisher SG. Endoscopic ultrasonography-identi-
fied celiac adenopathy remains a poor prognostic factor de-
spite preoperative chemoradiotherapy in esophageal adeno-
carcinoma. J Thorac Cardiovasc Surg 2006;131:65–72.
Reprinted with permission from Elsevier.
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It has been hypothesized that FDG uptake on PET
images reflects tumor cell metabolism and could be used as a
measure of tumor response and treatment efficacy. In one
study, the number of abnormalities visualized on pretreat-
ment PET was predictive of overall survival and disease-free
survival.46 FDG uptake on PET after preoperative chemother-
apy or radiochemotherapy has correlated with patient survival
and pathologic response.47 In the Swisher et al.47 study,
FDG-PET performed after radiotherapy but before surgery
showed acceptable sensitivity for tumor viability in patients
with 50% to 100% viable tumor cells. Disappointingly, how-
ever, FDG-PET did not have acceptable sensitivity in detect-
ing residual tumor with less than 50% of viable tumor.
Downey et al.48 reported that PET could detect metastatic
disease better than conventional imaging at initial evaluation
but not later and called for further studies correlating FDG-
PET with survival. Flamen et al.49 performed FDG-PET
before and after radiochemotherapy in 36 patients with lo-
cally advanced esophageal cancer and showed that response
to radiochemotherapy as shown on the scans was strongly
correlated with pathologic response and survival. Others have
shown that the metabolic activity indicated by FDG-PET
predicts tumor response in other types of cancer, including
head and neck cancer,50 lung cancer,51,52 and gastric cancer.53
Only a few published studies51,54 have attempted to
measure esophageal tumor response during radiochemo-
therapy. Wieder et al.54 showed that early esophageal tumor
response could be detected by FDG-PET. Their FDG-PET
images acquired 2 and 4 weeks after the start of treatment
showed continuous decrease of FDG uptake in the tumors of
responding patients. More important, the change in FDG
uptake seemed to level out between 4 weeks after the start of
treatment and after radiation but before surgery, indicating
that three sets of FDG-PET measurements may be sufficient
to establish the time course of tumor response: before radio-
chemotherapy, during and perhaps at the middle of radioche-
motherapy, and after radiochemotherapy before surgery. Pre-
liminary results from others54,55 have shown that it may be
possible to use serial PET to track tumor response in patients
with esophageal cancer. It was found that standard uptake
values (SUVs) from PET were significantly decreased at
mid-treatment (from 9.3  2.8 to 5.7  1.9) (p  .0001) and
at post-treatment (3.3  1.1) compared with baseline (p 
.0001). In patients found at histopathologic examination to
have responded (10% viable cells in the specimen), the
decrease in SUV between initiation and mid-treatment was
44%  15%, but in nonresponders, the decrease was only
21%  14% (p  0.0055). Mid-treatment SUVs also were
significantly correlated with survival (p  0.011). During the
study, responders experienced a 70% reduction (11%) in
SUVs, whereas nonresponders experienced only a 51%
(21%) reduction in SUVs. Wieder et al.54 showed that
inflammation of the normal esophagus was not a significant
problem in measuring the tumor response: diffuse esophageal
FDG uptake suggesting esophagitis was observed in only a
small number of patients (15% of patients after 14 days of
radiochemotherapy). The researchers concluded that the sig-
nificant correlation between response and mid-treatment
FDG-PET metabolic activity might be useful in stratifying
patients early in treatment and appropriately modifying the
therapeutic approach. Unfortunately, all studies only included
a small number of patients, and because this is the only study
published so far, results from this study need further valida-
tion from other groups. The value of reduction in tumor FDG
uptake on PET imaging early in the course of preoperative
radiochemotherapy also warrants further investigation, as it
was suggested to correlate well with tumor response to
preoperative chemotherapy.55 Although FDG-PET imaging
accurately predicts a pathologic complete response,19 at least
20% of patients with a normal preoperative PET will have
residual disease in the resected specimen (Figure 3).47
CONCURRENT RADIOCHEMOTHERAPY
Definitive Radiochemotherapy
Radiation therapy alone as definitive therapy results in
poor long-term results. However, radiotherapy with chemo-
therapy is superior to radiotherapy alone based on the results
of number of randomized trials.56–62 Most randomized trials
have used a cisplatin-based and 5-FU–based chemotherapy
combination (Table 2). The seminal study was the Radiation
Therapeutic Oncology Group (RTOG) trial 85-0156–58 that
compared the use of radiation only to 6400 cGy with a lower
dose radiation of 5000 cGy with concurrent cisplatin and
5-FU chemotherapy.56 Patients received four cycles of 5-FU
(1000 mg/m2 on days 1–4) and cisplatin (75 mg/m2 on day
1), but first two cycles were given with radiotherapy. The
postchemoradiotherapy chemotherapy was not well tolerated.
FIGURE 3. Postradiochemotherapy therapy 2-fluoro-2-de-
oxy-d-glucose positron emission tomography standardized
uptake value (mean  SEM) of the primary tumor as corre-
lated with the percentage of viable cells in pathologic speci-
mens (n  68) at the time of esophagectomy. Patients with
more than 50% tumor viability were found to have a signifi-
cantly higher average standardized uptake value compared
with the other patient groups. From Swisher SG, Erasmus J,
Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD,
Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe
WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
2-Fluro-2-deoxy-D-glucose positron emission tomography
imaging is predictive of pathologic response and survival af-
ter preoperative chemoradiation in patients with esophageal
carcinoma. Cancer 2004;101:1776–85. Reprinted with per-
mission from John Wiley & Sons, Inc.
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Grade 3 or higher toxicity occurred in 50% of the patients. At
a minimum of 5 years of follow-up, the overall survival rates
were 26% for patients who received combined modality
treatment and 0% for those who received radiotherapy alone.
Persistence of disease was the most common mode of treat-
ment failure; however, it was less common in the group receiv-
ing combined therapy (26%) than in the radiotherapy-alone
group (37%). Distant metastasis accounted for the first site of
treatment failure in 30% of the radiotherapy-alone group com-
pared with 16% of the combined-modality group (Figure 4).56,57
Higher doses of radiation may be needed for better local
control of squamous cell carcinoma.63 However, the optimal
radiation dose for adenocarcinoma is controversial. Coia et al.64
treated patients with 5-FU, mitomycin C, and 60 Gy of radiation,
and patients with clinically early-stage esophageal cancer (stages
I and II) were analyzed separately. This nonrandomized trial had
a very low local failure rate of 25%, a 5-year actuarial survival
rate of 30%, and a 5-year actuarial local relapse-free survival
rate of 70% for patients with stage I disease, but similar results
have been demonstrated using a lower radiation dose.65
A randomized study (RTOG 94-05)66 of 236 patients
(predominantly with squamous cell carcinoma) compared the
use of 64.8 Gy with chemotherapy versus 50.4 Gy with
chemotherapy. This trial failed to show any benefit in terms
of survival in the high-dose arm (Figure 5).66 The rates of
locoregional disease persistence (52% versus 56%) were
similar between the two study arms. Therefore, 50.4 Gy at 1.8
Gy per fraction 5 days per week is currently considered
standard for patients with esophageal cancer treated with
concurrent chemoradiation therapy.56–58,66
Although the intent-to-treat analysis of RTOG 94-05
showed no difference, there might have been some confound-
ing factors for this unexpected outcome. Future dose-related
questions may arise with improved radiation delivery tech-
niques. Retrospective studies, with all their limitations, suggest a
possible advantage of a higher radiation dose (Figure 6).67 In
addition, a meta-analysis by Ancona et al.68 provided additional
evidence of a relationship between a higher radiation dose and
increased likelihood of pathologic complete response. However,
only prospective evaluations can settle this issue.
TABLE 2. Randomized Trial of Radiochemotherapy and
Radiotherapy Alone
Study Treatment
No. of
Patients
5-yr
Survival (%)
Locoregional
Failure (%)
RTOG 85-0156–58 RCT 61 27 45
RCT 69 30 54
RT 62 0 68
ECOG 128259 RCT 59 9 Notreported
RT 60 7 Notreported
NCI Brazil60 RCT 28 16 61
RT 31 6 84
EORTC61 RCT 75 12 Notreported
RT 69 6
Scandinavia95 RCT 46 6 Notreported
RT 51 0
Pretoria62 RCT 34 5 mo (MST) Notreported
RT 36 6 mo (MST) Notreported
RTOG, Radiation Therapy and Oncology Group; ECOG, Eastern Cooperative
Oncology Group; NCI, National Cancer Institute; EORTC, European Organization for
Research and Treatment of Cancer; RCT, concurrent radiochemotherapy; RT, radiation
therapy; MST, median survival time.
FIGURE 4. Overall survival and local regional disease control in patients treated in the Radiation Therapy and Oncology
Group trial 85-01, a randomized trial of radiation and concurrent radiochemotherapy. There was no survivor at 3 years after
radiation only. The most common pattern of local failure was persistent disease. The local failure was high (50%–65%) in
both groups. LRC, locoregional control; CRTS, chemoradiotherapy  surgery; DMFS, distant metastasis-free survival; DFS,
disease-free survival; OS, overall survival. From Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK,
Cooper J, Byhardt R, Davis L. Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients
with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277–84. Reprinted with permission from the American
Society for Clinical Oncology; and Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R,
Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal
cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;
281:1623–7. Copyright © 1999 American Medical Association. All Rights Reserved. Reprinted with permission from the Ameri-
can Medical Association.
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Radiochemotherapy plus Surgery versus No
Surgery
The high local failure rate after radiochemotherapy
could be reduced if surgery is performed after radiochemo-
therapy. Liao et al.69 reported results from a retrospective
review of 132 consecutive patients with clinical stage II or III
esophageal cancer treated with concurrent radiochemo-
therapy; 60 of the patients underwent esophagectomy. The
median radiation dose was 50 Gy (range, 30–64.8 Gy) in the
definitive radiochemotherapy group and 45 Gy (range, 30–
50.4 Gy) in the radiochemotherapy plus esophagectomy
group. There were significant differences in median age,
histologic subtype, tumor location, and number of patients
with T4 disease between the two groups. For example,
patients who had definitive radiochemotherapy were older
(p  0.0004), more likely to have squamous cell carcinoma
rather than adenocarcinoma (p  0.000), upper thoracic or
cervical esophageal tumors (p  0.000), and T4 tumors (p 
0.024). At 5 years, patients who had undergone esophagec-
tomy had a better locoregional control (67.1% versus 22.1%,
p  0.000), disease-free survival (40.7% versus 9.9%, p 
0.000), and 5-year overall survival rates (52.6% versus 6.5%,
p  0.000), and median survival time (62 months versus 12
months, p 0.000.) compared with patients who did not
undergo esophagectomy. Surgical resection was an indepen-
dent predictor for improved locoregional control and overall
survival in the multivariate analysis. This advantage pre-
vailed even when patients were matched (Figure 7). Contrary
to the above-summarized finding, the 1992 to 1994 patterns
of care study suggested that at 4 years, there was no differ-
ence in survival between patients treated with radiochemo-
therapy plus surgery and those treated with definitive radio-
chemotherapy only.70
Two trials were designed to compare concurrent radio-
chemotherapy and concurrent radiochemotherapy followed
by surgery in locally advanced but resectable esophageal
cancer. The primary endpoint was overall survival, with the
hypothesis that both treatments were equivalent. In the FFCD
9102 trial,71 patients received concurrent radiochemotherapy
with 5-FU–cisplatin (days 1–5 and 22–26) and radiotherapy,
either protracted (46 Gy over 4.5 weeks) or split course (2 
15 Gy, days 1–5 and 22–26). Patients who achieved at least
a partial response with no contraindication for continuation of
concurrent radiochemotherapy or esophagectomy were ran-
domized between arm A (surgery) or arm B (continuation of
concurrent radiochemotherapy [three additional cycles of
5-FU–cisplatin] and protracted [20 Gy] or split-course [15
FIGURE 5. Overall survival (left) and time to first local failure or regional persistentdisease (right) in low and high radiation
dose groups from the Radiation Therapy and Oncology Group trial 94-05. There were no differences in survival or locore-
gional control. From Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen
DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer:
high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–74. Reprinted with permission from the Ameri-
can Society for Clinical Oncology.
FIGURE 6. Percentage of patients with locoregional failure
2 years after treatment as a function of radiation dose. The
dose-response curve seems to flatten at doses higher than
50 Gy. From Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter
M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P,
Cox JD, Komaki R. Dose-reponse relationship in locoregional
control for patients with stage II-III esophageal cancer
treated with concurrent chemotherapy and radiotherapy. Int
J Radiat Oncol Biol Phys 2005;61:656–64. Reprinted with
permission of Elsevier.
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Gy] radiotherapy). Between January of 1993 and November
of 2000, 259 patients were randomized out of 455 eligible
patients. There were no differences in 2-year survival rate
(34% versus 40%, adjusted OR  0.91; p  0.56) or median
survival (17.7 months versus 19.3 months) between arms A
and B. The mortality rate within 3 months after starting
induction treatment seemed to be higher than that reported in
the literature72 in the surgical arm (9% versus 1%, p 
0.002). This trial was limited by its short follow-up, uncon-
ventional radiation schema, and accrual in several centers,
some of which had a low surgical volume, thus potentially
contributing to a higher operative morbidity and mortality.
The German esophageal cancer study group trial22
randomized 189 patients with squamous cell carcinoma from
11 German institutions. All patients received induction che-
motherapy consisting of three cycles of 5-FU, leucovorin,
etoposide, and cisplatin, followed by radiochemotherapy (cis-
platin/etoposide  40 Gy), and then esophagectomy (arm A)
or followed by definitive chemoradiation consisting of cis-
platin/etoposide  more than 65 Gy (arm B). Treatment-
related death rates were 10% and 3.5% in arm A and arm B,
respectively. The overall survival was equivalent (log-rank
p  0.05). Cox regression analysis revealed clinical tumor
response to induction chemotherapy to be the single indepen-
dent prognostic factor for overall survival (hazard ratio 
0.30; 95% confidence interval, 0.19–0.47; p  0.0001)
(Figure 8).
In addition, several small phase II studies have reported
3-year survival with radiochemotherapy alone among patients
with operable esophageal cancer to be approximately 28%,
and long-term follow-up from the RTOG 85-01 study sug-
gests a 20% long-term survival rate for patients with locally
advanced esophageal cancer.73 These data suggest that defin-
itive radiochemotherapy is an acceptable alternative to sur-
gery and may provide long-term survival equivalent to that in
contemporary surgical series.
PREOPERATIVE RADIOCHEMOTHERAPY
Rationale
The biological behavior of adenocarcinoma of the esoph-
agus differs from that of squamous cell carcinoma. In a study
that included 235 esophageal cancer patients who underwent
preoperative radiochemotherapy and esophagectomy, Rohatgi et
al.74 reported similar rates of pathologic complete response in
patients with adenocarcinoma and those with squamous cell
carcinoma (29% and 31%, respectively). However, a more
favorable overall survival and distant metastasis-free survival
were observed only for adenocarcinoma and not squamous cell
carcinoma histology among patients who achieved pathologic
complete response.74 For those who undergo potentially curative
surgical resection, the 5-year survival rates can be as high as
30% to 40% but often are less than 20%.75
Traditionally, surgery is considered the primary treat-
ment for medically fit patients,76 but further improvements in
surgical outcomes are unlikely. The use of preoperative
radiochemotherapy has become common practice in the
United States. Hypothetically, this strategy addresses both
local and systemic cancer simultaneously.72,77 However, be-
cause of the lack of convincing phase III data, the role of
preoperative radiochemotherapy remains controversial. Hof-
setter et al.78 reviewed the experience at The University of
Texas M.D. Anderson Cancer Center with 1079 consecutive
esophagectomies over a 30-year period. They reported an
increasing use of neoadjuvant radiochemotherapy in the last
4 years of the study (59% versus 2%). This was accompanied
with an increased complete (R0) resection rate and median
survival. The authors concluded that preoperative radioche-
motherapy was associated with a longer median survival and
likelihood of a complete resection.
Nonrandomized Studies
Several prospective phase II studies39,79–85 have inves-
tigated preoperative radiochemotherapy for esophageal can-
FIGURE 7. Overall survival (OS) (A), disease-
free survival (DFS) (B), locoregional control
(LRC) (C), and distant metastasis-free survival
(DMFS) (D) for patients with matched pretreat-
ment characteristics treated with chemoradio-
therapy and esophagectomy (CRTS) and
patients treated with definitive chemoradio-
therapy (CRT). Radiation dose was 45 Gy in
both groups. From Liao Z, Zhang Z, Jin J, Ajani
JA, Swisher SG, Stevens CW, Ho L, Smythe R,
Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth
JA, Yao JC, Allen PK, Cox JD, Komaki R. Esoph-
agectomy after concurrent chemoradiotherapy
improves locoregional control in clinical stage
II or III esophageal cancer patients. Int J Radiat
Oncol Biol Phys 2004;60:1484–93. Reprinted
with permission from Elsevier.
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cer, using conventional radiotherapy dose fractionation to 45
Gy over 5 weeks and concurrent platinum and 5-FU–based
chemotherapy. Preoperative radiochemotherapy was associ-
ated with generally favorable results: R0 resection rates of
80% to 100%, complete pathologic response in 8% to 49% of
cases, and 2-year survival ranging from 27% to 62%. Patients
whose tumors achieved a pathologic complete response had
improved 5-year survival rates of between 55% and 70%.
Although local failures tended to be fewer than after surgery
alone, an apparent switch to more distant metastatic sites was
found (Table 3).3,36,39,79–94 However, these results have been
criticized for their small number of patients, differences in
radiation dose fractionation, and chemotherapy agents. For
example, split-course or accelerated regimens were used in
some studies.79,80,82,84 The 2-year survival rates of 27% to
62% do not differ significantly compared with the results
from definitive radiochemotherapy.57,66 Paclitaxel was used
in three studies and non–5-FU– based chemotherapy was
used in four studies.
Randomized Trials
At least nine randomized trials have compared preop-
erative radiochemotherapy followed by surgery versus sur-
gery alone41–43,95–100 (Table 4). Results of these trials conflict,
with most of the trials showing no survival benefit using
combined therapy and one trial showing a survival benefit in
favor of preoperative radiochemotherapy.41,42,98
The trial conducted by Walsh et al.41 evaluated 113
patients. In the preoperative radiochemotherapy arm, patients
received 40 Gy over 3 weeks and two courses of 5-FU and
cisplatin given at weeks 1 and 6. Surgery was preformed
around week 8. There was one preoperative death and four
postoperative deaths in the preoperative radiochemotherapy
arm, whereas there were only two postoperative deaths in the
surgery alone arm. The 3-year survival rates were 32% and
6% in the preoperative radiochemotherapy and surgery-alone
groups, respectively (p  0.01). The trial conducted by Urba
et al.42 studied 100 patients (75% with adenocarcinoma). In
the preoperative radiochemotherapy arm, patients received 45
Gy over 3 weeks (1.5 Gy per fraction, twice daily); cisplatin
and vinblastine were given at weeks 1 and 3; 5-FU was given
from days 1 to 21. Preoperative radiochemotherapy was
associated with grade 3 to 4 neutropenia in 78% and neutro-
penic fever in 39% of patients. In addition, 16% of patients
needed blood transfusions, and 63% required feeding tube
placement. There were three postoperative deaths, two in
preoperative radiochemotherapy arm and one in surgery arm.
FIGURE 8. Kaplan-Meier plots showing overall survival from
the date of randomization among patients allocated to preop-
erative radiochemotherapy and surgery (arm A, n  86) or ra-
diochemotherapy without surgery (arm B, n  86) (A), survival
as randomized among patients treated according to their treat-
ment arm excluding crossover patients (arm A, n  75; arm B,
n  81) (B) , and the freedom from locoregional progression
among patients allocated to preoperative radiochemo-
therapy and surgery (arm A) or radiochemotherapy without
surgery (arm B) (C). EUS, endoscopic ultrasonography. From
Stahl M, Wilke H, Fink U, Stuschke M, Walz MK, Siewert JR,
Molls M, Fett W, Makoski HB, Breuer N, Schmidt U, Niebel
W, Sack H, Eigler FW, Seeber S. Combined preoperative che-
motherapy and radiotherapy in patients with locally ad-
vanced esophageal cancer. Interim analysis of a phase II trial.
J Clin Oncol 1996;14:829–37. Reprinted with permission
from the American Society for Clinical Oncology.
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The 3-year survival rates were 30% and 16% in the preop-
erative radiochemotherapy arm and surgery arms, respec-
tively (p  0.15). The trial conducted by Burmeister et al.43
evaluated 256 patients (157 with adenocarcinoma). In the
preoperative radiochemotherapy arm, patients received 35
Gy over 3 weeks and one 5-FU–cisplatin course at week 1.
The median survivals were 21.7 and 18.5 months in the
preoperative radiochemotherapy and surgery arms, respec-
tively (p  0.38).
However, these trials had the same limitations as the
nonrandomized trials: small numbers of patients and thus
limited statistical power to detect a difference between the
arms, relatively poor preoperative staging; lack of well-
defined stratification factors; wide variation in the chemother-
apy agents, radiation dose, and schedule; and short follow-up
duration. In the only study that has reported a survival benefit
from preoperative radiochemotherapy, the 6% overall sur-
vival in the surgery-alone arm was significantly inferior to
that of other trials (Table 4). Furthermore, the survival rates
of patients treated with preoperative radiochemotherapy
ranged from 25% to 35%,41,42,98 similar to the survival rates
of 25% to 27% after radiochemotherapy alone,57,66 although
a survival benefit was suggested in a recent meta-analysis.101
Carefully designed randomized trials are needed to address
this problem. Bosset et al.100 reported on an ongoing clinical
trial conducted by the Foundation Franc¸aise de Cance´rologie
Digestive and the European Organization for Research and
Treatment of Cancer, in which patients with stage IIA and IIB
esophageal cancer (either squamous cell or adenocarcinoma)
are randomized either to a preoperative radiochemotherapy
arm (45 Gy over 5 weeks and two 5-FU–cisplatin courses) or
a surgery-only arm. The trial was designed to enroll total 380
patients to detect a 3-year increased survival rate from 35%
with surgery only to 50% in the preoperative radiochemo-
therapy arm. To date, 121 patients have been included. It is
hoped that this trial will answer the question more defini-
tively. Therefore, although preoperative radiochemotherapy
has become a common practice in the community and in large
academic centers in the United States recently, it should not
be considered the standard of care for cancer of the esophagus
at present.
A recent meta-analysis included nine randomized, con-
trolled trials with total 1116 patients of preoperative radio-
chemotherapy plus surgery with surgery alone for the treat-
ment of esophageal cancer. A random-effects model was
used, and the OR was the principal measure of effect. Sys-
tematic quantitative review was done for outcomes unique to
the neoadjuvant radiochemotherapy treatment group, such as
pathologic complete response. There was a complete patho-
logic response to radiochemotherapy in 21% of patients.
Compared with surgery alone, neoadjuvant radiochemo-
therapy and surgery improved 3-year survival and reduced
locoregional cancer recurrence. It was associated with a
lower rate of esophageal resection, but a higher rate of
complete (R0) resection. There was a nonsignificant trend
toward increased treatment mortality with neoadjuvant radio-
chemotherapy. Concurrent administration of neoadjuvant
chemotherapy and radiotherapy was superior to sequential
radiochemotherapy treatment.102
Three-Step Strategies
One important observation in patients treated with
preoperative radiochemotherapy is that the pattern of failure
has changed from locoregional persistent disease or recur-
rence to distant metastasis.69 To overcome this problem,
Ajani et al.103 proposed the concept of a three-step strategy,
TABLE 3. Selected Nonrandomized Studies of Preoperative Radiochemotherapy of the Esophagus
Study No. of Patients Chemotherapy Drugs Radiation Dose (Gy) R0 (%) pCR (%) 2-yr OS (%) LF (%) DM (%)
Poplin et al.86 113 CF 30 49 16 28 — —
Naunheim et al.87 47 CF 30–36 72 17 40 (3 yr) — —
Urba et al.79 24 CF 49 100 8 — 12.5 25
Hoff et al.89 68 CF 30 18 51 6 25
Forastiere et al.80 43 CF 45 84 23 55 14 40
Chiappori et al.88 87 CF 30 — 17 — — —
Bates et al.90 39 CF 45 90 46 40 (3 yr) — —
Stahl et al.36 72 CFLE 40 67 22 33 (3 yr)
Blanke et al.91 21 CPac 30 — 16 — — —
Keller et al.81 46 CF 60 72 17 27 — —
Bedenne et al.92 96 CF 30 82 20 40 (25% 5 yr)
Urba et al.93 69 CPac 45 19 51 — —
Heath et al.39 42 CF 44 83 26 62 5 43
Adelstein et al.84 63 CPac 45 93 23 30 — —
Safran et al.94 41 CPac 39.6 — 29 42 — —
Kleinberg et al.83 92 CFPac 44 87 33 57 8 41
Meluch et al.85 129 CFPac 45 78 49 47 2 30
Choi et al.82 46 CFPac 58.5 95 38 50 23 42
R0, complete resection; pCR, percentage of pathologic complete response; OS, percentage of overall survival; LF, percentage of local failure; DM, percentage of distant
metastasis; C, cisplatin; F, 5-fluorouracil; L, leucovorin; E, etoposide; Pac, paclitaxel.
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with up-front induction chemotherapy followed by preoper-
ative radiochemotherapy. Jin et al.104 reported a retrospective
study comparing additional systemic chemotherapy before
concurrent radiochemotherapy with preoperative radioche-
motherapy alone for surgically resectable esophageal cancer.
Patients who received induction chemotherapy had higher
rates of complete pathologic response, locoregional control,
distant metastasis-free survival, disease-free survival, and
overall survival. Paclitaxel and irinotecan, two agents that are
active against metastatic disease and with the ability to
increase the proportion of cells in the G2-M phase of the cell
cycle (thereby enhancing radiosensitivity), seem to be partic-
ularly promising for this approach and clinically feasible.105
Swisher et al.35 reported the long-term outcome of induction
chemotherapy, radiochemotherapy, and surgery for 38 pa-
tients with locoregionally advanced esophageal cancer in a
phase II trial. Patients initially received two cycles of pacli-
taxel, 5-FU, and cisplatin, followed by radiochemotherapy,
consisting of radiation (45 Gy) with 5-FU and cisplatin
during radiation. Surgical resection was performed 4 to 6
weeks after the completion of the chemoradiotherapy. The
most patients had T3 tumors (87%), N1 (66%) adenocarci-
noma (84%) by EUS. Thirty-seven patients (97%) completed
the planned chemotherapy and radiochemotherapy, and 35
patients (92%) underwent surgery, with a 30-day periopera-
tive mortality rate of 6% (two of 35 patients). A pathologic
complete response or microscopic residual carcinoma (10%
viable) was found in 25 (71%) of 35 patients and was
associated with a disease-free survival rate of 72% at 3 years
and 51% at 5 years. The same group106 recently reported
results in 43 patients with esophageal cancer who received
two cycles of irinotecan and cisplatin, followed by 45 Gy of
radiation concurrent with 5-FU and paclitaxel. By using this
strategy, dysphagia was relieved in 50% of patients after
induction chemotherapy, and an R0 resection was achieved in
36 patients who underwent surgery, with two postoperative
deaths. Two-year survival was 42%, and among patients with
recurrent disease, 80% had a distant failure. Similar results
using this three-step strategy were also reported by Bains et
al.107 for 41 patients who received two cycles of induction
paclitaxel and cisplatin, followed by 50.4 Gy of radiation
combined with cisplatin and paclitaxel. Dysphagia improved
in 92% of patients after induction chemotherapy, with grade
3 esophagitis in only 5% of patients. The addition of induc-
tion chemotherapy to preoperative radiochemotherapy was a
novel approach in the treatment of esophageal cancer (Table
TABLE 4. Randomized Trials of Preoperative Radiochemotherapy with Surgery Alone in Patients with Localized Esophageal
Cancer
Study No. of Patients Chemotherapy Drugs Radiotherapy Dose (Gy) Median Survival (mo) 3-yr Survival(%) p
Nygaard et al.95 NS
Surgery alone 41 NA 9
Preoperative RCT 47 CB 35 NA 17
Le Prise et al.96 NS
Surgery alone 41 10 14
Preoperative RCT 45 CF 20 10 19
Apinop et al.97 NS
Surgery alone 34 7 20
Preoperative RCT 35 CF 40 10 26
Walsh et al.41 0.01
Surgery alone 55 11 6
Preoperative RCT 58 CF 40 16 32
Bosset et al.98 NS
Surgery alone 139 19 37
Preoperative RCT 143 C 37 19 39
Law et al.99 NS
Surgery alone 30 27 NA
Preoperative RCT 30 CF 40 26 NA
Urba et al.42 0.15
Surgery alone 50 18 16
Preoperative RCT 50 CFV 45 17 30
Burmeister et al.43 0.38
Surgery alone 128
Preoperative RCT 128 CF 35 2219 NA
Bosset et al.100 NA NA Ongoing study
Surgery alone 380 planned
Preoperative RCT 121 enrolled CF 45
RCT, radiochemotherapy; pCR, percentage of pathologic complete response; OS, percentage of overall survival; LF, percentage of local failure; DM, percentage of distant
metastasis; C, cisplatin; B, bleomycin; F, 5-fluorouracil; L, leucovorin; E, etoposide; V, vinblastine; NA, not available.
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5).35,106–109 It is hoped that if the local effect of preoperative
radiochemotherapy is sufficiently pronounced, then a survival
benefit may be observed.110
ADVERSE EFFECTS OF RADIOCHEMOTHERAPY
Limitations of this approach relate to toxicity (poten-
tially excluding patients from surgery) and increased periop-
erative morbidity. In current clinical practice, postoperative
mortality after esophageal resection in high-volume centers is
expected to be less than 5%.75,76 In a randomized trial
conducted to evaluate preoperative radiochemotherapy for
esophageal squamous cell cancer,98 an increased disease-free
survival was observed without overall survival benefit, prob-
ably due to an excessive number of postoperative deaths
(generally pulmonary complications) in the preoperative ra-
diochemotherapy arm. One possible explanation was the
unconventional radiotherapy fractionation, with a 3.7-Gy
daily dose. Further analysis showed that postoperative mor-
tality was also significantly related to the number of patients
treated at each participating center.98
Treatment-related acute toxicity results from biological
effects on rapidly dividing cells within (e.g., esophagogastric
mucosa, lung, heart) and outside (e.g., bone marrow) the
irradiated volume. The severity of toxic effects depends on
the volume of critical tissues irradiated, radiotherapy frac-
tionation (accelerated fractionation increase toxicity), and the
selection of chemotherapeutic agents, dose, and method of
delivery. Acute toxicity that results in interruptions to the
treatment schedule may compromise the efficacy of concur-
rent preoperative radiochemotherapy. Late-responding tis-
sues with slowly dividing cells (e.g., connective tissues,
capillary endothelium) may express long-term toxic effects
several months or even years after completion of treatment.
Late toxicity depends on the radiation dose, the fractional
dose (an increased risk is seen for doses 2 Gy), and choice
of chemotherapeutic agent.110
Lung Toxicities
Preoperative radiochemotherapy and esophagectomy
was associated with 2% to 18% mortality generally secondary
to sepsis, pneumonia, and adult respiratory distress syn-
drome.82,84 Pulmonary complications are the most common
serious morbidity after esophagectomy and the leading cause
of postoperative mortality among patients treated with sur-
gery for esophageal cancer. The incidence of postoperative
pulmonary complications is 30% or higher,98 and the associ-
ated in-hospital mortality rate is 55%.111 Risk factors such as
poor performance status, poor lung function, and advanced
age have been identified for use as strict patient selection
criteria for surgery.112 Additionally, prolonged duration of
operation and excessive blood loss were associated with
increased morbidity and mortality after esophagectomy.112
High radiation dose or large fractionation dose may
account for the higher mortality rates observed in selected
series.81,84,94 In one study in which patients received split-
course radiation with 3.5 Gy per fraction, 11 of 18 patients
who survived surgical resection suffered from major radia-
tion-induced pleural and pericardial complications.81 A recent
meta-analysis showed that postoperative mortality is higher
in patients treated with radiochemotherapy plus surgery than
in those treated with surgery alone,113 although this conclu-
sion follows mainly from the increased mortality in the
radiochemotherapy arm of the largest randomized trial in the
analysis, in which both high radiation dose fractions and high
cisplatin doses were used.43
Lee et al.114 were the first to report that postoperative
pulmonary complications increased significantly when more
than 40% of the total lung received radiation doses higher
than 10 Gy (V10 40%). The postoperative pulmonary
complications defined as pneumonia or adult respiratory dis-
tress syndrome that developed postoperatively within 30 days
after surgery before discharge was the clinical endpoint of
this study.115 In light of the results from that study, we
modified our practice in radiation treatment planning dose
constraints to keep V10 below 40% in patients treated sub-
sequently in our clinic, while at the same time escalating the
total radiation dose from 45 Gy to 50.4 Gy. Wang et al.116
recently reevaluated the effects of clinical and dosimetric
factors on the incidence of postoperative pulmonary compli-
cations. The results indicated that the volume of lung spared
from (or not receiving) doses of 5 Gy or higher (VS5) was the
only independent predictive factor associated with this com-
plication for esophageal cancer patients treated with concur-
rent chemoradiotherapy followed by surgery: the smaller the
volume of lung receiving doses less than 5 Gy, the higher the
TABLE 5. Results of Three-Step Treatment for Locally Advanced Esophageal Cancer
Study
No. of
Patients
Induction
Chemotherapy
Drugs
Concurrent
Chemotherapy
Drugs
Radiation
Dose (Gy) % pCR
3-yr
OS (%)
5-yr
OS (%)
Median Survival
Time (mo)
Bains et al.107 41 C, Pac C, Pac 50.4 22 NA NA NA
Swisher et al.35 38 C, F, Pac C, F 45 21 63 39 NA
Ajani et al.106 43 Irin F, Pac 50.4 28 NA NA 22.125.6
(pCR/pPR)18.5
(pPR)
Ilson et al.108 19 C, Irin C, Irin 50.4 27 NA NA NA
Pasini et al.109 47 Doc P, F Doc P, F 50 29.8 NA NA NA
% pCR, percentage of pathologic complete response; pPR, partial pathologic response; OS, overall survival; C, cisplatin; Pac, paclitaxel; Irin, irinotecan; Doc, docetaxel; P,
platinum; F, 5-fluorouracil; NA, not available.
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incidence of postoperative pulmonary complications. This
conclusion was reached with the use of an / ratio of 10 Gy
in computing the lung dose volume histograms because
surgical pulmonary complication was considered as an
acute event compared with radiation pneumonitis, in which
case an / ratio of 3 Gy was often used. Nevertheless, the
same conclusion was reached with the lung dose volume
histograms computed using an / ratio of 3 Gy or direct
physical dose, indicating that the results were insensitive
to the use of the / factors and to whether biological
equivalent dose or physical doses were used in the statis-
tical analysis (Figure 9).116
Findings from this study suggest that the volume of
remaining undamaged functional lung, rather than the volume
of damaged functional lung, determines postoperative pulmo-
nary function. In other words, patients who have a small lung
volume to start with may be at higher risk of experiencing
pulmonary complications even if their relative V5 is low.
Strong evidence of this is that, in that study, patient sex was
associated with the incidence of postoperative pulmonary
complications on univariate analysis but not on multivariate
analysis. As noted, this may have been because the total lung
volume was smaller in females than in males, thus making the
volume spared in female patients smaller than in males
despite similar lung volumes exposed to radiation. This in
turn suggests that patients with a smaller lung volume and
less functional reserve may be more susceptible to postoper-
ative pulmonary complications. Thus, to reduce the risk of
postoperative pulmonary complications, more attention may
have to be paid not only to the dose volume histogram of the
lung but also to the total lung volume and nonirradiated lung
FIGURE 10. Simulation computed tomography slices with radiation therapy plan for treating a patient with distal esophageal
cancer and the Gated Myocardial Perfusion Image scans performed 11 months after completion of radiation therapy. The area
of ischemia in the inferior wall of the heart (arrow) was included in the 4000 to 5000 cGy isodose line. Reprinted by permis-
sion of the Society of Nuclear Medicine from Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J,
Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated
myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 2006;47(11):1756–62. Figure 2.
FIGURE 9. Incidence of postoperative pulmonary complica-
tions versus lung volume spared from doses of 5 Gy or
higher (VS5). The dashed curve represents the fit of the logis-
tic model to the data (incidence of pulmonary complications
versus VS5). The solid dots represent the observed incidence
of pulmonary complications in each of five equal (n  22)
patient subgroups plotted at the mean value of VS5 for the
group. The horizontal error bars represent 1 SD of the
mean VS5 in each group. The vertical error bars represent
1 SD calculated from the observed incidence assuming bi-
nomial statistics. From Wang SL, Liao Z, Vaporciyan AA,
Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki
R. Investigation of clinical and dosimetric factors associated
with postoperative pulmonary complications in esophageal
cancer patients treated with concurrent chemoradiotherapy
followed by surgery. Int J Radiat Oncol Biol Phys 2006;64:
692–9. Epub 2005 Oct 19. Reprinted with permission from
Elsevier.
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volume during treatment planning.116 Applying these data
sets to the normal tissue complication probability model,
Tucker et al.117 reported that the risk of postoperative pul-
monary complications was most significantly associated with
small absolute volumes of lung spared from doses 5 Gy or
more (VS5), i.e., exposed to doses less than 5 Gy. However,
bootstrap analysis found no significant difference in the
quality of this model and fits based on other dosimetric
parameters, including mean lung dose, effective dose, and
relative volume of lung receiving 5 Gy or more, probably
because of correlations among these factors. However, this
study was limited by its retrospective nature and small patient
and event number; therefore, the conclusions need to be
further substantiated with additional, preferably prospective
data. In patients who were treated with radiochemotherapy
alone, systemic chemotherapy before concurrent radiochemo-
therapy was found to be associated with increased CTC 3.0
grade 2 or higher treatment-related pneumonitis.118
Esophagus Toxicities
Accurate assessment of the incidence and severity of
esophagitis in esophageal cancer patients is generally difficult
because the symptoms that are used to define esophagitis
(dysphagia, odynophagia) are not specific and might be
obscured by effects of the tumor itself. 5-FU–based chemo-
therapy regimens have been associated with severe esophagi-
tis in as high as 80% of patients, and 50% of all patients
treated needed nutritional support, intravenous hydration, and
unplanned hospitalization.39,80,82 Esophagitis is lower in stud-
ies used non–5-FU–containing chemotherapy regimen, such
as paclitaxel, with no compromise in rates of complete
resection or pathologic response.84,91,94,119
Cardiac Toxicity
There is increasing evidence that cardiac toxicity could
manifest as one of the acute events for esophageal cancer
patients treated by radiochemotherapy and/or surgery. A
recent retrospective study reviewed and analyzed a total of
101 patients treated with definitive radiochemotherapy with-
out surgery in 1998–2004, and 49 patients who had preop-
erative radiochemotherapy and myocardial perfusion scans.
Cardiac abnormality was evaluated based on clinical records
or perfusion imaging, if available, for the patient population.
The commonly occurring cardiac toxicity was pericardial
effusion with incidence of 27.7%. The pericardial effusion
developed within 15 months after radiation therapy, with
median onset times of 5.3 months. The risk of pericardial
effusion was found to be associated with the mean pericardial
dose (P  0.002) and an array of dose-volume points for the
pericardium from 5 to 45 Gy, possibly because of the corre-
lation among the dosimetric factors. In addition, in the sur-
gery group, 49 patients had distal esophageal tumor behind
the heart and underwent gated myocardial perfusion SPECT
imaging prior to surgery. Among this subgroup, 25 patients
were treated with concurrent radiochemotherapy and 24 pa-
tients had surgery alone. In the matched two subgroups of
surgical patients, myocardium perfusion defect including
ischemia and/or scarring was identified from SPECT images
in 42.3% of patients treated with radiochemotherapy, in
contrast to only 4% of patients not treated with radiochemo-
therapy (P  0.001). The onset of myocardium perfusion
defect ranged from 1 to 48 months, with a mean of 7.5
months and a median of 3 months (Figure 10).121
SUMMARY
In Western countries, the incidence of esophageal
adenocarcinoma in the lower esophagus or gastroesopha-
geal junction has increased 5% to 10% recently. In the
United States, it is the seventh leading cause of cancer
mortality in men, causing 10,530 deaths annually or 5.1
deaths per 100,000 men and 1.2 deaths per 100,000
women. Its 5-year survival rate (10% to 14.3% overall)
is lower than that of 15 other cancers cited by the Amer-
ican Cancer Society, with only liver and pancreatic cancers
identified as more deadly. Celiac lymph node involvement
at the time of diagnosis suggests an unfavorable outcome;
therefore, better locoregional staging with the use of EUS,
CT-PET, and newer imaging modalities may help select
appropriate candidates. Approximately 50% of these pa-
tients present with locoregional disease, for which radio-
chemotherapy is a critical part of the management, either
as a neoadjuvant or definitive measure. It is well estab-
lished that radiochemotherapy is the treatment of choice
for nonsurgical patients, with survival rates similar to
those after surgery alone. However, persistent disease after
definitive concurrent radiochemotherapy remains a major
pattern of locoregional failure. Adding surgery to defini-
tive concurrent radiochemotherapy has increased locore-
gional control without a clear benefit for overall survival.
Neoadjuvant radiochemotherapy has been shown to down-
stage tumors and increase the complete resection rate.
However, this treatment approach remains investigational
because there is no survival benefit realized with such an
aggressive treatment. Pulmonary, cardiac, and mucosal
toxicities have been reported, and most of them are asso-
ciated with radiation dosimetric parameters. Pathologic
complete response is a strong indicator of favorable sur-
vival. Methods to predict and to assess early the tumor
response to neoadjuvant therapy and thus allow individu-
alized treatment have attracted extensive research efforts,
including the use of biomarkers and functional images.
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